|Bid||0.3900 x 21500|
|Ask||0.3950 x 800|
|Day's Range||0.3590 - 0.4075|
|52 Week Range||0.3100 - 1.7800|
|Beta (5Y Monthly)||0.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 28, 2022 - Apr 01, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.67|
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 40% and 0.96%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the first quarter of 2022.
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?